Press Releases
Corporate News
2/6/2013
BIOLINE LAUNCHES ISOLATE II (DNA & RNA ISOLATION)
11/28/2012
SensiFAST™ GENOTYPING KIT EXCEED THE LIMIT
9/27/2010
MLS Successfully Manufacturers 2nd cGMP Production Campaign
8/31/2010
RSV M37 CLINICAL CHALLENGE VIRUS MANUFACTURED BY MLS
8/12/2010
MLS successfully manufactures norovirus Vlp Drug substances for Ligocyte
7/28/2010
MERIDIAN LIFE SCIENCE EXPANDS R&D AND CONTRACT MANUFACTURING FACILITIES IN MEMPHIS
7/20/2010
MERIDIAN BIOSCIENCE ACQUIRES LEADING MANUFACTURER AND DISTRIBUTOR OF MOLECULAR REAGENTS
5/19/2009
MLS Achieves Production Specification for the Australian Neonatal Rotavirus Vaccine
5/14/2009
MLS to Present at Bio 2009
1/23/2009
MLS Expands cGMP Facility
6/16/2008
MLS Completes Vybion Product Acquisition
5/13/2008
Meridian Signs Agreement to acquire Vybion Proteins
Product News
4/22/2013
New Infectious Disease Catalog
3/29/2013
Introducing Additional Fermentation Capabilities
2/27/2013
MAb to Calprotectin L1 Protein
2/4/2013
Immunoassay Blocking Agents - Update
1/4/2012
MAbs to CRP
9/27/2011
Varicella-Zoster Virus
8/31/2011
High Performance PCR Reagents
7/25/2011
MAbs to CA19-9
6/8/2011
MLS Offers Coenzymes, Enzymes & Substrates
4/27/2011
Campylobacter jejuni Products
3/21/2011
Dengue Product Offerings
2/25/2011
Bioline Launches SensiFast™ Real-Time PCR Kits
1/17/2011
MAbs to Prostate Specific Antigen (PSA) Pairs for Immunoassay
10/12/2010
Contract Manufacturers Bank on New Initiatives to Boost Capabilities
10/5/2010
MLS complete a 2nd clinical cGMP production lot RV3 rotavirus vaccine
9/13/2010
Reducing Errors in Immunoassay Testing - GEN Article
9/7/2010
In vivo and In vitro MAb Contract Manufacturing
8/4/2010
MLS Launches New MAbs to Chlamydia
7/12/2010
Purified Cytomegalovirus Antigen
5/6/2010
Performance Gains & Cost Savings w/TRU Block
4/28/2010
MAb ot Rotavirus, VP6
4/19/2010
MAbs to Rubella in Purified Form
3/29/2010
MAbs to RSV Nucleoprotein
2/23/2010
MLS Introduces Lyophilized M-IgG
1/26/2010
MAb to Cryptococcus neoformans
12/18/2009
TRU Block Effectively Blocks RF
11/11/2009
MAbs to Adenovirus Type 40, 41, and Both
9/21/2009
Pandemic Influenza Strain Antibodies & Peptides
9/3/2009
Protein Products in Yeast
7/29/2009
Blocking Agents - Part 2
Swine Flu 2009 Update
5/11/2009
Blocking Agents Part 1
5/4/2009
Publication Cites use of MLS Toxoplasma gondii Antibody and Protein
4/14/2009
Researchers use MLS Purified Mouse Apo A1 as a standard
3/24/2009
High Performance Clones for Hormones
3/18/2009
Hormones and Steroids Product Line
3/10/2009
MLS Influenza Viruses Used to Test for Antibodies in Vaccine Delivery Study
2/25/2009
New MLS Infectious Disease Antigen Product Brochure
2/16/2009
TRU Block - Novel Active Blocker Released by MLS
1/26/2009
hCG Antigens and Antibodies
1/13/2009
Specification Sheets with Images
12/22/2008
Custom Antibody Production: In Vivo and In Vitro
12/11/2008
Publication Cites Use of HCV NS-5A and NS-4 MAbs
11/25/2008
Publication Cites MLS ApoB and A1AT Antibody use in HCV/VLDL Research
11/4/2008
FDA Publication Cites MLS Ab to Bioterrorism Agents
9/22/2008
TORCH Antigens
8/28/2008
Herpes Simplex Virus
8/6/2008
New Infectious Disease e-Catalog
7/26/2008
HBV and Apoptotic Caspase Activity
6/28/2008
Chicken Antibodies (Animal Immunoglobulins)
4/4/2008
Escherichia coli
3/13/2008
Hepatitis C
2/25/2008
MAb Production Brochure
2/6/2008
Bone/Calcium Metabolism
1/29/2008
Infectious Disease Focus (TB/HIV)
1/15/2008
Autoimmune Diseases